Abivax

At the core of the science behind Abivax is miR-124, a #microRNA that is well characterized in the scientific literature. miR-124 interacts with specific messenger RNA targets, decreasing their translation into their respective proteins. For more information about our science, visit https://lnkd.in/eKZnghcg.

What an incredible week at #DDW2024! Thank you to all who stopped by our booth—we loved discussing our work and research in #IBD.

Read what Sheldon Sloan, MD, M Bioethics, Abivax Chief Medical Officer had to say about the role of small molecule drugs in #autoimmune and chronic conditions like #ulcerativecolitis with European Pharmaceutical Review:

#IBD impacts quality of life for millions worldwide. We are proud to be developing a potential new treatment option for people with chronic inflammatory diseases, like #InflammatoryBowelDisease. Learn more about our commitment to people with IBD: https://lnkd.in/ev-3RDxR #WorldIBDDay

Tomorrow is #WorldIBDDay. #IBD is a term used to describe conditions characterized by chronic inflammation of the #GI tract, such as ulcerative colitis and Crohn’s disease. Abivax strives to develop therapies to effectively treat inflammatory bowel diseases and improve the lives of people with IBD.

We are looking forward to attending Digestive Disease Week® (DDW) in Washington, DC. Visit booth 529 to learn more about Abivax and connect with fellow #IBD researchers. #DDW2024

This #InternationalDayOfFamilies we are highlighting the unique role families play in supporting a loved one or close friend with #IBD. Your support can make a monumental difference in the health and happiness of people living with IBD. Today, we would also like to honor the importance of your dedication and resilience.

We’re excited to share the launch of our new corporate website. Explore its new look and the latest updates at https://www.abivax.com.

Meet three of our outstanding Abivax employees who embody dedication, innovation, and teamwork, shaping the future of our company with their exceptional talents and passion. Thank you for your commitment to developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases.

On #WorldHealthDay, Abivax celebrates biotech innovations for people with chronic inflammatory diseases. With our lead drug candidate, obefazimod, in Phase 3 trials and a recent US IPO under our belt, we're fueled to advance healthcare, improve lives, and shape a healthier future.